drugset / Trial / NCT01605773

Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

NCT01605773

Phase 4 Completed 51 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to compare the effect of repaglinide on postprandial lipemia in subjects with type 2 diabetes.

Timeline

Start
2001-11-08
Primary completion
2003-03-13
Completion
2003-03-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glyburide Small molecule
Subject Repaglinide Small molecule